Skip to main content

Advertisement

Fig. 2 | BMC Medicine

Fig. 2

From: Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients

Fig. 2

HRMAS NMR spectra of pancreatic adenocarcinoma (PA). a PA without neoadjuvant chemotherapy (n = 44), b PA with neoadjuvant chemotherapy (n = 62). The spectra metabolic contents are directly comparable because the intensity of each spectrum was normalized with respect to the weight of the analyzed sample. For display purposes, the amplitude of the lactate peak at 1.33 ppm was graphically shortened. Metabolite assignments are given in Table 1

Back to article page